Research Papers:

Induction chemotherapy followed by concurrent chemoradiation and nimotuzumab for locoregionally advanced nasopharyngeal carcinoma: preliminary results from a phase II clinical trial

Jian-feng Huang, Fu-zheng Zhang, Qin-zhou Zou, Le-yuan Zhou, Bo Yang, Jian-jun Chu, Jia-hua Yu, Hao-wen Zhang, Xiao-peng Yuan, Guo-mei Tai, Fen-ju Liu _ and C-M Charlie Ma

PDF  |  HTML  |  How to cite

Oncotarget. 2017; 8:2457-2465. https://doi.org/10.18632/oncotarget.13899

Metrics: PDF 2226 views  |   HTML 2198 views  |   ?  


Jian-feng Huang1,2,*, Fu-zheng Zhang2,*, Qin-zhou Zou2, Le-yuan Zhou2, Bo Yang2, Jian-jun Chu2, Jia-hua Yu1, Hao-wen Zhang1, Xiao-peng Yuan3, Guo-mei Tai3, Fen-ju Liu1 and C-M Charlie Ma4

1 Department of Radiobiology, School of Radiation Medicine and Protection and Jiangsu Provincial Key Laboratory of Radiation Medicine and Protection, Medical College of Soochow University, Collaborative Innovation Center of Radiation Medicine of Jiangsu Higher Education Institutions and School for Radiological and Interdisciplinary Sciences (RAD-X), Soochow University, Suzhou, China

2 Department of Radiation Oncology, Affiliated Hospital of Jiangnan University, Wuxi, China

3 Department of Radiation Oncology, Nantong Tumor Hospital, Affiliated Tumor Hospital of Nantong University, Nantong, China

4 Department of Radiation Oncology, Fox Chase Cancer Center, Philadelphia, PA, USA

* These authors have contributed equally to this work

Correspondence to:

Fen-ju Liu, email:

Keywords: nasopharyngeal carcinoma, nimotuzumab, chemoradiotherapy, induction chemotherapy

Received: October 13, 2016 Accepted: November 24, 2016 Published: December 10, 2016


Overexpression of epidermal growth factor receptor can be found in more than 80% of patients with locoregionally advanced nasopharyngeal carcinoma and is associated with shorter survival. In this work, we evaluated the feasibility of adding nimotuzumab to chemoradiation in locoregionally advanced nasopharyngeal carcinoma. Twenty-three patients with clinically staged T3-4 or any node-positive disease were enrolled. They were scheduled to receive one cycle of induction chemotherapy followed by intensity-modulated radiotherapy, weekly administration of nimotuzumab and concurrent chemotherapy. Results showed that all patients received a full course of radiotherapy, 19(82.6%)patients completed the scheduled neoadjuvant and concurrent chemotherapy, and 22(95.7%) patients received ≥6 weeks of nimotuzumab. During the period of concurrent chemoradiation and nimotuzumab, grade 3-4 toxicities occurred in 14(60.9%) patients: 8 (34.8%) had grade 3-4 oral mucositis, 6(26.1%) had grade 3 neutropenia, and 1(4.3%) had grade 3 dermatitis. No acne-like rash was observed. With a median follow-up of 24.1 months, the 2-year progression-free survival and overall survival were 83.5% and 95.0%, respectively. In conclusion, concurrent administration of chemoradiation and nimotuzumab was well-tolerated with good compliance. Preliminary clinical outcome data appear encouraging with favorable normal tissue toxicity results comparing with historical data of concurrent chemoradiation plus cetuximab.

Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 13899